Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations

Myelodysplastic syndromes (MDS) patients with DEAD-box helicase 41 (DDX41) mutations have been reported to be treated effectively with lenalidomide; however, there are no randomized studies to prove it. Venetoclax and azacitidine are safe and effective in high-risk MDS/AML. In this study, we evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Wang, Zhijian Xiao, Tiejun Qin, Zefeng Xu, Yujiao Jia, Shiqiang Qu, Bing Li, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
Myelodysplastic syndromes
DDX41
venetoclax
azacitidine
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2024.2338509
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2024.2338509

Similar Items